Evotec refines analyst expectations, shares trade under 5 euros on Xetra

Evotec opens the week with a clear consensus picture on Xetra. Analyst estimates and technical signals remain cautious while the biotech group continues its restructuring and AI-driven research push.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:41.

Evotec (DE0005664809) starts the new trading week on Xetra with a subdued share price below 5 euros while the analyst consensus remains markedly above the market level. The biotech group continues to digest its May capital measures and restructuring, as current estimates from several houses show.

What analysts currently expect

Analyst data compiled by wallstreet-online shows an average target price around 8.45 euros for Evotec, based on 31 published studies that still imply a substantial upside to the current quotation. The distribution remains clearly positive, with most brokers rating the stock at Buy or Outperform according to that overview.

Evotec is followed by a broad international broker community that includes houses such as Deutsche Bank, Berenberg and JPMorgan, which regularly update their models after capital measures or strategic announcements. The consensus reflects expectations that the company will gradually improve profitability once the current restructuring phase and portfolio streamlining take effect.

How the shares trade on Xetra and NASDAQ

On German platforms such as Stuttgart, Evotec shares recently traded around 4.59 euros, representing a short-term decline of roughly 0.7 percent versus the previous close according to finanzen.net. On Xetra and regional exchanges, the stock has also recorded a weak performance over the past month, with a decline of more than 10 percent on a 30-day view.

The US-listed Evotec ADR with ticker EVO on NASDAQ closed the previous session at 2.64 US dollars, up just over 3 percent, giving the company a market capitalization of about 938 million dollars according to TradingKey. Technical analysis from that source currently sends a Sell signal overall, with six moving-average based sell indications versus no buy signals.

The business behind Evotec

Evotec generates its revenue primarily as a drug discovery and development partner for large pharmaceutical and biotech companies, structured in the EVT Execute and EVT Innovate segments. The company runs research platforms in areas such as small molecules, biologics and precision medicine, increasingly integrating in silico and AI methods into its workflows.

Where the shares trade today

The Evotec shares (DE0005664809) trade on 2026-06-23, 14:30 on the Stuttgart exchange at 4.59 euros.

Key data on the Evotec shares

• Company: Evotec SE
• ISIN: DE0005664809
• WKN: 566480
• Ticker: EVT
• Trading venue: Xetra
• Price (as of 2026-06-23, 14:30): 4.59 euros
• Market cap: 938 million US dollars (as of 2026-06-22)
• Sector / industry: Biotechnology & Medical Research
• Index membership: TecDAX
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument.